A Phase I, Open-label, Multi-center Study to Evaluate the Pharmacokinetics and Safety of Oral Panobinostat in Patients With Advanced Solid Tumors and Varying Degrees of Renal Function.
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2015
At a glance
- Drugs Panobinostat (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 21 Nov 2014 Results presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- 05 Nov 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 21 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History